&lt;sup&gt;125&lt;/sup&gt;I seed brachytherapy versus external beam radiation therapy for the palliation of painful bone metastases of lung cancer after one cycle of chemotherapy progression

Xiang, Zhanwang; Wang, Lifei; Yan, Huzheng; Zhong, Zhihui; Liu, Wangkai; Mo, Zhiqiang; Gao, Fei; Zhang, Fujun

doi:10.2147/ott.s154973

Cited by 15 publications

(12 citation statements)

References 28 publications

(29 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CT-guided RSI has been widely employed as a local treatment strategy in those with advanced NSCLC. 22 Relative to conventional external beam radiation, RSI has been shown to more effectively control large, inoperable NSCLC tumours and to improve overall patient quality of life relative to conventional radiotherapy and chemotherapy. 23 In this meta-analysis, we examined differences in the clinical efficacy of combination chemotherapy and CTguided RSI treatment relative to chemotherapy alone in advanced-stage NSCLC patients.…”

Section: Discussionmentioning

confidence: 99%

Radioactive seeds insertion with chemotherapy for advanced non‐small‐cell lung cancer: A meta‐analysis

Yang

et al. 2020

Clinical Respiratory J

View full text Add to dashboard Cite

Lung cancer (LC) is the most common cause of cancer-related death among humans. 1-3 Low-dose computed tomography (CT) is often used to screen for LCs, but even so, most patients with LC present with advanced-stage disease that is not eligible for curative resection. 4 Indeed, under 20% of non-small-cell LC (NSCLC) patients are eligible to undergo curative surgical resection. 4 Patients not eligible for curative respective treatment instead typically undergo chemotherapy and/or radiotherapy, but traditional chemotherapy is not an effective approach to controlling inoperable NSCLC. 5,6 Additionally, external beam radiotherapy is generally associated with

show abstract

Section: Discussionmentioning

confidence: 99%

Radioactive seeds insertion with chemotherapy for advanced non‐small‐cell lung cancer: A meta‐analysis

Yang

et al. 2020

Clinical Respiratory J

View full text Add to dashboard Cite

show abstract

“…Seed implants have also been carried out in additional sites including the breast, liver, head and neck, mediastinum, and gastrointestinal tract, and the results are summarized in Table 2 58–67 …”

Section: Resultsmentioning

confidence: 99%

Low dose rate permanent seed brachytherapy: tracing its evolution and current status

Banerjee

Kataria

Goyal

et al. 2020

Precision Radiation Oncology

View full text Add to dashboard Cite

A recent surge in publications on low dose rate permanent seed brachytherapy prompted us to review the currently available literature in order to provide a summary of the therapy. To this end, we composed a comprehensive review on the available English language publications in PubMed, EMBASE, and Google Scholar. The general principles of seed brachytherapy are discussed, along with radiobiology and technical aspects. Seed brachytherapy has been increasingly used in various sites for primary treatment, and is considered to be particularly useful in cases of reirradiation and otherwise untreatable malignancies. In recent decades, there have been considerable advances in the technology used in seed brachytherapy, including steps to prevent the migration of seeds, reduce personnel exposure to radiation, and use of sophisticated 3-D planning for better dosimetric results, which have ultimately translated into better clinical outputs. Technical advances in seed brachytherapy have lagged behind those in external beam radiotherapy and high dose rate brachytherapy; however, there is renewed interest due to encouraging clinical results in the primary setting, as well as reirradiation for recurrent disease across several sites.

show abstract

“…Radioactive 125 I seed implantation has advantages of relieving tumor-related symptoms and improving QOL (34). A study shows that, for advanced NSCLC patients after failure of firstline chemotherapy, 125 I seed implantation could improve DCR and relieve chest pain, cough, and shortness of breath without increasing the incidence of treatment-related adverse effects (35).…”

Section: Discussionmentioning

confidence: 99%

Oligorecurrence Non–small Cell Lung Cancer After Failure of First-Line Chemotherapy: Computed Tomography–Guided 125I Seed Implantation vs. Second-Line Chemotherapy

et al. 2020

View full text Add to dashboard Cite

Purpose: To compare the efficacy and safety of computed tomography (CT)-guided 125 I seed implantation with second-line chemotherapy in treatment of oligorecurrence non-small cell lung cancer after failure of first-line chemotherapy.Methods: Data of oligorecurrence non-small cell lung cancer patients after failure of first-line chemotherapy at two institutions were retrospectively reviewed from January 2013 to July 2018. A total of 53 patients who received the treatment of 125 I seed implantation or second-line chemotherapy were eligible for this study. In group A, 25 patients, 84 lesions, received CT-guided permanent 125 I seed implantation, whereas in group B, 28 patients, 96 lesions, received second-line chemotherapy. The outcomes were measured in terms of disease control rate, overall survival, quality of life, and complications.Results: The median follow-up period was 13 months (range, 5-42 months). Disease control rate in group A was higher than that in group B (70.8 vs. 42.3%, P = 0.042) at 6 months after treatment. The median overall survival was 12.8 months (95% confidence interval, 10.5-15.1 months) in group A and 15.2 months (95% confidence interval, 12.2-18.2 months) in group B, with no significant difference (P = 0.847). Since the fourth month, the number of patients in group A with a non-decreasing Karnofsky Performance Scale score was more than that in group B (P < 0.05). The incidence of grade 3 or higher complications especially hematologic toxicity in group A was significantly lower than that in group B (P < 0.05).Conclusion: Radioactive 125 I seed implantation is safe and feasible in selected non-small cell lung cancer patients with oligorecurrence after failure of first-line chemotherapy and seems to provide a better long-term quality of life in these patients compared with second-line chemotherapy.

show abstract

<sup>125</sup>I seed brachytherapy versus external beam radiation therapy for the palliation of painful bone metastases of lung cancer after one cycle of chemotherapy progression

Cited by 15 publications

References 28 publications

Radioactive seeds insertion with chemotherapy for advanced non‐small‐cell lung cancer: A meta‐analysis

Radioactive seeds insertion with chemotherapy for advanced non‐small‐cell lung cancer: A meta‐analysis

Low dose rate permanent seed brachytherapy: tracing its evolution and current status

Oligorecurrence Non–small Cell Lung Cancer After Failure of First-Line Chemotherapy: Computed Tomography–Guided 125I Seed Implantation vs. Second-Line Chemotherapy

Contact Info

Product

Resources

About